Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study

BACKGROUND: This phase 3 trial is the first to evaluate the efficacy and safety of treatment with the systemic TNF‐α inhibitor, adalimumab, for Chinese patients with moderate‐to‐severe plaque psoriasis. METHODS: In the 12‐week, double‐blind, placebo‐controlled Period A, patients were randomized 4 :...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, L., Gu, J., Zheng, J., Zheng, M., Wang, G., Xi, L.‐Y., Hao, F., Liu, X.‐M., Sun, Q.‐N., Wang, Y., Lai, W., Fang, H., Tu, Y.‐T., Sun, Q., Chen, J., Gao, X.‐H., Gu, Y., Teixeira, H.D., Zhang, J.‐Z., Okun, M.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215651/
https://www.ncbi.nlm.nih.gov/pubmed/27504914
http://dx.doi.org/10.1111/jdv.13746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215651/
https://www.ncbi.nlm.nih.gov/pubmed/27504914
http://dx.doi.org/10.1111/jdv.13746

Ejemplares similares